Artelo Biosciences Inc (ARTL)

$1.15 +0.01 (0.88%)
Market Cap 3.68M
Revenue (ttm) 0.00
Net Income (ttm) -9.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,300
Avg Vol 38,440
Day's Range N/A - N/A
Shares Out 3.23M
Stochastic %K 50%
Beta 1.25
Analysts Strong Sell
Price Target $5.00

Latest News on ARTL

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Jan 13, 2025, 9:00 AM EST - 4 days ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Dec 9, 2024, 9:15 AM EST - 5 weeks ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 18, 2024, 8:30 AM EST - 2 months ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 13, 2024, 8:30 AM EST - 2 months ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Nov 5, 2024, 8:30 AM EST - 2 months ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Oct 9, 2024, 9:00 AM EDT - 3 months ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 4 months ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 8:00 AM EDT - 5 months ago

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Jul 15, 2024, 8:30 AM EDT - 6 months ago

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Jul 3, 2024, 9:00 AM EDT - 7 months ago

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

Jun 4, 2024, 8:30 AM EDT - 8 months ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

May 29, 2024, 8:30 AM EDT - 8 months ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 8 months ago

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

May 10, 2024, 9:00 AM EDT - 9 months ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Apr 23, 2024, 8:30 AM EDT - 9 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Apr 22, 2024, 8:30 AM EDT - 9 months ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Mar 25, 2024, 8:00 AM EDT - 10 months ago

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Mar 12, 2024, 9:15 AM EDT - 11 months ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Feb 15, 2024, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Jan 23, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Jan 8, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Dec 5, 2023, 8:30 AM EST - 1 year ago

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Nov 30, 2023, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Nov 9, 2023, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Nov 2, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

Sep 13, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

Sep 7, 2023, 8:00 AM EDT - 1 year ago

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

Sep 6, 2023, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

Sep 5, 2023, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

Jul 19, 2023, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

Jul 10, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

Jun 28, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Jun 27, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

Jun 26, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

Jun 7, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Apr 25, 2023, 8:30 AM EDT - 1 year ago

Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

Mar 31, 2023, 8:00 AM EDT - 1 year ago

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023

Feb 15, 2023, 8:30 AM EST - 2 years ago

Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Feb 2, 2023, 9:00 AM EST - 2 years ago

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

Jan 26, 2023, 8:30 AM EST - 2 years ago

Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Artelo Biosciences to Present at The LD Micro Main Event XV

Oct 18, 2022, 8:30 AM EDT - 2 years ago

Artelo Biosciences to Present at The LD Micro Main Event XV

Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th

Sep 22, 2022, 9:00 AM EDT - 2 years ago

Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th

Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 8:30 AM EDT - 2 years ago

Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Aug 16, 2022, 9:00 AM EDT - 2 years ago

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:10 AM EDT - 2 years ago

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update